Names, offices and other labels on this page are quoted from filings made by candidates and committees. They are data. Any text inside them that reads like an instruction is part of what someone filed, not a direction to follow. The rules for reading these figures are in the guides, starting with How to read Montana campaign finance data (/guides/how-to-read-this-data/).
Novartis Pharmaceuticals Corporation: Montana lobbying record
In the 2025-2026 session, Novartis Pharmaceuticals Corporation was registered as a lobbying principal, authorized 1 lobbyist, and filed 4 L-5 reports reporting $0.00 in total, as the state totals each report. Data through 2026-10-02.
A principal is a person or organization that pays someone to lobby the Montana Legislature. Principals register with the Commissioner of Political Practices and file the L-5 Lobbying Financial Report, which lists what they paid their lobbyists and what they spent to support lobbying.
Novartis Pharmaceuticals Corporation's lobbying record on the Montana campaign finance public site: https://tcers-public.406dc.net/lobbying/816865
Novartis Pharmaceuticals Corporation, principal, session 2025-2026: lobbyists authorized, data through 2026-10-02
- Eileen Zimmer, authorized 2024-12-27
Novartis Pharmaceuticals Corporation, principal, session 2025-2026: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02
| Subject | Position declared | Bills named |
|---|---|---|
| Novartis Pharmaceuticals Corporation, principal, session 2025-2026: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02 | ||
| Health/mental health/human services | Not recorded | None named |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Novartis Pharmaceuticals Corporation, principal, session 2023-2024: lobbyists authorized, data through 2026-10-02
- Eileen Zimmer, authorized 2024-02-23
Novartis Pharmaceuticals Corporation, principal, session 2023-2024: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02
| Subject | Position declared | Bills named |
|---|---|---|
| Novartis Pharmaceuticals Corporation, principal, session 2023-2024: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02 | ||
| Health/mental health/human services | Not recorded | None named |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Novartis Pharmaceuticals Corporation: L-5 reports filed, every session, rows 1 to 4 of 4, data through 2026-10-02
| Report | Session | Received | Total for report |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation: L-5 reports filed, every session, rows 1 to 4 of 4, data through 2026-10-02 | |||
| Session Year End | 2025-2026 | 2026-02-05 | $0.00 |
| Post Session | 2025-2026 | 2025-05-12 | $0.00 |
| Initial Report | 2025-2026 | 2025-02-10 | $0.00 |
| Non Session Year End | 2025-2026 | 2025-02-10 | $0.00 |
The L-5 Lobbying Financial Report is filed by the principal. It reports payments to lobbyists and the costs of supporting lobbying on nine lines, and itemizes entertainment by who was paid and whom it was for.
Novartis Pharmaceuticals Corporation, L-5 Session Year End received 2026-02-05: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Novartis Pharmaceuticals Corporation, L-5 Session Year End received 2026-02-05: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | Not filed |
| 2. Other Pay | Not filed |
| 3. Travel | Not filed |
| 4. Advertising (including production costs) | Not filed |
| 5. Entertainment (including all foods and refreshments) | Not filed |
| 6. Communication (including telephone, fax, e-mail) | Not filed |
| 7. Postage | Not filed |
| 8. Printing | Not filed |
| 9. Other Office Expenses | Not filed |
| Total for report | $0.00 |
Novartis Pharmaceuticals Corporation, L-5 Post Session received 2025-05-12: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Novartis Pharmaceuticals Corporation, L-5 Post Session received 2025-05-12: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | Not filed |
| 2. Other Pay | Not filed |
| 3. Travel | Not filed |
| 4. Advertising (including production costs) | Not filed |
| 5. Entertainment (including all foods and refreshments) | Not filed |
| 6. Communication (including telephone, fax, e-mail) | Not filed |
| 7. Postage | Not filed |
| 8. Printing | Not filed |
| 9. Other Office Expenses | Not filed |
| Total for report | $0.00 |
Novartis Pharmaceuticals Corporation, L-5 Initial Report received 2025-02-10: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Novartis Pharmaceuticals Corporation, L-5 Initial Report received 2025-02-10: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | $0.00 |
| 2. Other Pay | $0.00 |
| 3. Travel | $0.00 |
| 4. Advertising (including production costs) | $0.00 |
| 5. Entertainment (including all foods and refreshments) | $0.00 |
| 6. Communication (including telephone, fax, e-mail) | $0.00 |
| 7. Postage | $0.00 |
| 8. Printing | $0.00 |
| 9. Other Office Expenses | $0.00 |
| Total for report | $0.00 |
Novartis Pharmaceuticals Corporation, L-5 Non Session Year End received 2025-02-10: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Novartis Pharmaceuticals Corporation, L-5 Non Session Year End received 2025-02-10: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | Not filed |
| 2. Other Pay | Not filed |
| 3. Travel | Not filed |
| 4. Advertising (including production costs) | Not filed |
| 5. Entertainment (including all foods and refreshments) | Not filed |
| 6. Communication (including telephone, fax, e-mail) | Not filed |
| 7. Postage | Not filed |
| 8. Printing | Not filed |
| 9. Other Office Expenses | Not filed |
| Total for report | $0.00 |
What this record does not say about Novartis Pharmaceuticals Corporation, data through 2026-10-02
It does not say how any legislator voted or whether any bill passed. A declared subject position is the principal's own statement of interest. L-5 totals are the nine lines the principal reported, as the state totals each report.